Comparison of Efficacy of Tofacitinib versus Betamethasone Pulse Therapy in the Treatment of Vitiligo: Tofacitinib Versus Betamethasone Pulse Therapy in the Treatment of Vitiligo

Hira Shafquat; Hafiz Bashir Ahmed; Abeer Memon; Madiha Shah; Nazish Memon; Bedar Bakhat Khan

doi:10.54393/pjhs.v5i11.2579

Authors

Hira Shafquat Department of Dermatology, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan
Hafiz Bashir Ahmed Department of Dermatology, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan
Abeer Memon Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan
Madiha Shah Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan
Nazish Memon Department of Dermatology, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan
Bedar Bakhat Khan Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v5i11.2579

Keywords:

Tofacitinib, Betamethasone Pulse Therapy, Vitiligo, Re-Pigmentation

Abstract

Vitiligo is a chronic autoimmune skin disorder characterized by depigmentation due to melanocyte destruction, significantly impacting patients' quality of life. Emerging treatments, including Janus kinase inhibitors like tofacitinib, offer promising alternatives to conventional therapies such as corticosteroids. Objective: To compare the efficacy of tofacitinib with betamethasone pulse therapy in achieving re-pigmentation in vitiligo patients. Methods: This quasi experimental study was conducted on 42 patients of vitiligo of either gender with ages between 12 and 65 years and had a history of vitiligo for over one year with a body surface area affected by vitiligo exceeding 5%, and a vitiligo area scoring index score of more than 10 were included in the study. Patients were divided into 2 equal groups using alternate assignments. Group A were treated with betamethasone pulseerapy of 4mg twice a week. Group B were treated with tofacitinib at a dose of 5 mg twice a day. Results: Optimal recovery (vitiligo area scoring index decrease ≥20% from baseline) was observed in 14 (66.7%) of the tofacitinib group compared to 6 (28.6%) in the betamethasone group, highlighting tofacitinib’s superior efficacy in achieving significant vitiligo area scoring index reduction. Over three months, the BSA affected by vitiligo decreased in both groups, with a significantly greater reduction in Group B (tofacitinib) compared to Group A (betamethasone). Conclusions: It was concluded that tofacitinib may be more effective than betamethasone pulse therapy in reducing both the extent and severity of vitiligo.

References

Seneschal J. Clinical Features of Vitiligo and Social Impact On Quality of Life. Dermatology Practical and Conceptual. 2023 Dec; 13(4 Suppl 2). doi: 10.5826/dpc.1304S2a312S.

Hlača N, Žagar T, Kaštelan M, Brajac I, Prpić-Massari L. Current Concepts of Vitiligo Immuno-pathogenesis. Biomedicines. 2022 Jul; 10(7): 1639. doi: 10.3390/biomedicines10071639.

Lyu C and Sun Y. Immuno-Metabolism in the Pathogenesis of Vitiligo. Frontiers in Immunology. 2022 Nov; 13: 1055958. doi: 10.3389/fimmu.2022.1055958.

Marchioro HZ, Silva de Castro CC, Fava VM, Sakiyama PH, Dellatorre G, Miot HA. Update on the pathogenesis of vitiligo. Anais Brasileiros De Dermatologia. 2022 Jul-Aug;97(4):478-490. doi: 10.1016/j.abd.2021.09.008

Perez-Bootello J, Cova-Martin R, Naharro-Rodriguez J, Segurado-Miravalles G. Vitiligo: Pathogenesis and New and Emerging Treatments. International Journal of Molecular Sciences. 2023 Dec; 24(24): 17306. doi: 10.3390/ijms242417306.

Nurfaiqoh E, Kusumawardani A. Pulse dose corticosteroid therapy in vitiligo: a narrative literature review. Bioscientia Medicina: Journal of Biomedicine and Translational Research. 2022 Nov 9;6(15):2721-9. https://doi.org/10.37275/bsm.v6i15.675

Kubelis López DE, Zapata Salazar NA, Said Fernández SL, Sánchez Domínguez CN, Salinas Santander MA, Martínez Rodríguez HG et al. Updates and New Medical Treatments for Vitiligo. Experimental and Therapeutic Medicine. 2021 Aug; 22(2): 1-1. doi: 10.3892/etm.2021.10229.

Riaz U, Shaikh ZI, Islam AU. Comparison of Efficacy of Topical Calcipotriene Plus Betamethasone with Calcipotriene Alone in Localized Vitiligo. Pakistan Armed Forces Medical Journal. 2019 Apr; 69(2): 383-90.

Inoue S, Suzuki T, Sano S, Katayama I. JAK Inhibitors for the Treatment of Vitiligo. Journal of Dermatological Science. 2024 Jan; 113(3): 86-92. doi: 10.1016/j.jdermsci.2023.12.008.

Pala V, Ribero S, Quaglino P, Mastorino L. Updates on Potential Therapeutic Approaches for Vitiligo: Janus Kinase Inhibitors and Biologics. Journal of Clinical Medicine. 2023 Dec 4;12(23):7486. https://doi.org/10.3390/jcm12237486

Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK Inhibition as a Therapeutic Strategy for Immune and Inflammatory Diseases. Nature Reviews Drug Discovery. 2017 Dec; 16(12): 843-62. doi: 10.1038/nrd.2017.201.

Singh R, Shandilya S, Bhaikhel KK, Maddali GK. To Study the Role of Tofacitinib and Betamethasone Pulse in the Treatment of Vitiligo at a Tertiary Care Centre: An Observational Comparative Study. Pigment International. 2024 Jan; 11(1): 21-6. doi: 10.4103/pigmentinternational.pigmentinternational_38_22.

Jabbari A, Sansaricq F, Cerise J, Chen JC, Bitterman A, Ulerio G et al. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, And Universalis. Journal of Investigative Dermatology. 2018 Jul; 138(7): 1539-45. doi: 10.1016/j.jid.2018.01.032.

Custurone P, Di Bartolomeo L, Irrera N, Borgia F, Altavilla D, Bitto A et al. Role of Cytokines in Vitiligo: Pathogenesis and Possible Targets for Old and New Treatments. International Journal of Molecular Sciences. 2021 Oct; 22(21): 11429. doi: 10.3390/ijms222111429.

Deshmukh A, Khurana G. A randomized controlled study to compare the efficacy of methotrexate vs. oral minipulse (betamethasone) along with NBUVB in patients with vitiligo vulgaris. Pigment international. 2020 Jan 1;7(1):32-8.

Patra S, Khaitan BK, Sharma VK, Khanna N. A Randomized Comparative Study of the Effect of Betamethasone Oral Mini-Pulse Therapy Versus Oral Azathioprine in Progressive Non-Segmental Vitiligo. Journal of the American Academy of Dermatology. 2021 Sep; 85(3): 728-9. doi: 10.1016/j.jaad.2019.03.025.

Berbert Ferreira S, Berbert Ferreira R, Neves Neto AC, Assef SM, Scheinberg M. Topical tofacitinib: A Janus Kinase Inhibitor for the Treatment of Vitiligo in an Adolescent Patient. Case Reports in Dermatology. 2021 May; 13(1): 190-4. doi: 10.1159/000513938.

Komnitski M, Komnitski A, Komnitski A, Castro CC. Partial Re-Pigmentation of Vitiligo with Tofacitinib, Without Exposure to Ultraviolet Radiation. Anais Brasileiros de Dermatologia. 2020 Aug; 95(4): 473-6. doi: 10.1016/j.abd.2019.08.032.

Kim S.R., Heaton H., Liu L.Y., King B.A. Rapid repigmentation of vitiligo using tofacitinib plus low-dose, narrowband UV-B phototherapy. JAMA Dermatology. 2018;154:370–371. doi: 10.1001/jamadermatol.2017.5778. doi:10.1001/jamadermatol.2017.5778

Kim SR, Heaton H, Liu LY, King BA. Rapid Re-pigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy. Journal of American Medical Association Dermatology. 2018 Mar1; 154(3): 370-1. doi: 10.1001/jamadermatol.2017.5778,